MYOS Corporation is engaged in the discovery, development and commercialization of therapeutic products, nutritional supplements and other technologies to improving the health and performance of muscle tissue. The Company earns revenues through the sale and distribution of MYO-T12. The Company is continuing to develop additional channels for distributing its products in other markets. As of December 31, 2013, the Company earns revenues from the distribution of MYO-T12, its platform dietary supplement product. As of December 31, 2013, the Company markets two Bionutritional products to the general public. The Company is selling its platform ingredient MYO-T12, branded as MYO-X, through national specialty retailers and e-tailers such as GNC, Vitamin Shoppe, bodybuilding.com and Amazon.com. The Company�s product pipeline seeks to develop formulations of its myostatin-inhibiting products to target specific mechanisms involved in maintaining lean muscle mass and function.